The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma
NCT ID: NCT02525965
Last Updated: 2016-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
194 participants
INTERVENTIONAL
2015-08-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For now, there has been many controversies on the impact about the width of liver resection margin on curative effect. Poon has proven that there is no significant difference in recurrence rate between resection margin \> 1cm and resection margin \< 1cm. However, Shi et al published a randomized controlled trial: for patients with a solitary tumor, resection margin \> 2cm can reduce the recurrence rate after hepatectomy. This is also the only randomized clinical trial study which proves increaseing resection margin will benefit the clinical results at present. A meta analysis consist of 18 studies proves that whether the resection margin has a relationship with a benefit clinical result still needs a further verification.
On the other hand, because microvascular invasion (MVI) is the direct evidence of the micro metastasis in hepatocellular carcinoma, it will decrease recurrence rate for the patients with a high MVI risk, if the investigators increase the resection margin width during the surgery? Shanghai Eastern Hepatobiliary Surgery Hospital which the investigators affiliated with had ever conducted a retrospective analysis on consecutive 3263 patients with HCC hepatectomy, the results indicated that a wide resection margin(≥1cm)can benefit those patients with microvascular invasion , nevertheless, the benefit will not present if patients are without microvascular invasion.
Further and better proofs still needs to approval this consequence, of course. In the past,another study of the ours, published online in the Journal of the American Medical Association Surgery, established a nomogram to predict the presence of microvascular invasion in the early-stage hepatocellular carcinoma, it will efficiently predict the occurrence of microvascular invasion in the hepatocellular carcinoma (HCC) fulfilled the Milan criteria. In consideration of the above basis, the investigators will implement a randomized controlled trial to certificate whether it could really reduce the recurrence rate after liver resection for participants with a high MVI risk during the surgery, if the method participants chose is a wide resection margin.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wide resection margin >1cm
Surgical removal of lesions choosing the method of wide resection margin \>1cm
Wide resection margin >1cm
Surgical removal of lesions choosing the method of wide resection margin \>1cm
Narrow resection margin <1cm
Surgical removal of lesions choosing the method of narrow resection margin \<1cm
Narrow resection margin <1cm
Surgical removal of lesions choosing the method of wide resection margin \<1cm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Wide resection margin >1cm
Surgical removal of lesions choosing the method of wide resection margin \>1cm
Narrow resection margin <1cm
Surgical removal of lesions choosing the method of wide resection margin \<1cm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with HCC according to the criteria of American Association for the Study of Liver Diseases (AASLD).
* Fulfill the Milan criteria.
* High-risk of microvascular invasion (MVI).
* Nomogram score \>200.
* Performance status score is 0-1 before the surgery.
* Without or mild liver cirrhosis and the liver function is Child A class.
* Without any other treatments such as TACE、PEI、PRFA before the surgery.
Exclusion Criteria
* Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction.
* Subjects accepting other trial drugs or participating in other clinical trials.
* Patients refuse to join our trial.
* Female with pregnancy or during the lactation period.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eastern Hepatobiliary Surgery Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ShenFeng
vice president of the Eastern Hepatobiliary Surgery Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shen Feng, MD
Role: STUDY_CHAIR
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shen Feng, MD
Role: primary
Wu Dong, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EHBHLRM-2015-8-10
Identifier Type: -
Identifier Source: org_study_id